CN112062780A - 一类具有免疫调节功能的芳香化合物的制备和应用 - Google Patents
一类具有免疫调节功能的芳香化合物的制备和应用 Download PDFInfo
- Publication number
- CN112062780A CN112062780A CN201910503368.2A CN201910503368A CN112062780A CN 112062780 A CN112062780 A CN 112062780A CN 201910503368 A CN201910503368 A CN 201910503368A CN 112062780 A CN112062780 A CN 112062780A
- Authority
- CN
- China
- Prior art keywords
- substituted
- group
- unsubstituted
- compound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000007365 immunoregulation Effects 0.000 title abstract description 4
- 150000001491 aromatic compounds Chemical class 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 156
- 230000000694 effects Effects 0.000 claims abstract description 11
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 65
- 229910052757 nitrogen Inorganic materials 0.000 claims description 53
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 229910052717 sulfur Inorganic materials 0.000 claims description 47
- -1 Oxo Chemical class 0.000 claims description 43
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 37
- 125000005842 heteroatom Chemical group 0.000 claims description 37
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 229910052701 rubidium Inorganic materials 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 230000006472 autoimmune response Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 claims description 2
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 claims description 2
- 241000764238 Isis Species 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 239000000243 solution Substances 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 39
- 238000006243 chemical reaction Methods 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 30
- 238000005160 1H NMR spectroscopy Methods 0.000 description 26
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 239000003208 petroleum Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 6
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000012270 PD-1 inhibitor Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 4
- 208000017604 Hodgkin disease Diseases 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 239000012668 PD-1-inhibitor Substances 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 230000002584 immunomodulator Effects 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 208000037819 metastatic cancer Diseases 0.000 description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229940121655 pd-1 inhibitor Drugs 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- 206010046885 vaginal cancer Diseases 0.000 description 4
- 208000013139 vaginal neoplasm Diseases 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MZYBRBUWADMPLI-YJBOKZPZSA-N (2S,4S)-1-[[4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridin-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound C1=C(C2=CC=CC=C2)C(Cl)=C(NC2=NC=CC3=C2N=C(S3)CN2[C@@H](C[C@@H](C2)O)C(=O)O)C=C1 MZYBRBUWADMPLI-YJBOKZPZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- USZJYWXGRXFJJX-UHFFFAOYSA-N 2-[[3-(2-methyl-3-phenylanilino)thieno[3,2-b]pyridin-6-yl]methylamino]ethanol Chemical compound CC1=C(C=CC=C1NC1=CSC=2C1=NC=C(C=2)CNCCO)C1=CC=CC=C1 USZJYWXGRXFJJX-UHFFFAOYSA-N 0.000 description 2
- RSWHNXUMOHKARR-UHFFFAOYSA-N 2-[[4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[5,4-c]pyridin-2-yl]methylamino]ethanol Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1SC(=N2)CNCCO)C1=CC=CC=C1 RSWHNXUMOHKARR-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- NDMHPSBWIFCVTR-UHFFFAOYSA-N 3-aminothieno[3,2-b]pyridine-6-carbonitrile Chemical compound N#CC1=CN=C2C(N)=CSC2=C1 NDMHPSBWIFCVTR-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FENKVFUVDQNQIO-UHFFFAOYSA-N 4-chloro-2-(methoxymethyl)-[1,3]thiazolo[4,5-c]pyridine Chemical compound ClC1=NC=CC2=C1N=C(S2)COC FENKVFUVDQNQIO-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- YHTJQXJSYZYURQ-UHFFFAOYSA-N ClC1=C(C=CC=C1B1OC(C(O1)(C)C)(C)C)C1=NC(=C(C=O)C=C1)OC Chemical compound ClC1=C(C=CC=C1B1OC(C(O1)(C)C)(C)C)C1=NC(=C(C=O)C=C1)OC YHTJQXJSYZYURQ-UHFFFAOYSA-N 0.000 description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000224466 Giardia Species 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102000004289 Interferon regulatory factor 1 Human genes 0.000 description 2
- 108090000890 Interferon regulatory factor 1 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PROUUAILGOOTLB-UHFFFAOYSA-N Nc1cccc(-c2ccccc2)c1Cl Chemical compound Nc1cccc(-c2ccccc2)c1Cl PROUUAILGOOTLB-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 206010034299 Penile cancer Diseases 0.000 description 2
- 241000233805 Phoenix Species 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046392 Ureteric cancer Diseases 0.000 description 2
- 206010046431 Urethral cancer Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 201000005188 adrenal gland cancer Diseases 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 244000053095 fungal pathogen Species 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 2
- 229960005079 pemetrexed Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 238000012284 sample analysis method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 201000002314 small intestine cancer Diseases 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- RHAHNDIBVWTCNK-CVDCTZTESA-N (2S,4S)-4-hydroxy-1-[[3-(2-methyl-3-phenylanilino)thieno[3,2-b]pyridin-6-yl]methyl]pyrrolidine-2-carboxylic acid Chemical compound O[C@H]1C[C@H](N(C1)CC=1C=C2C(=NC=1)C(=CS2)NC=1C(=C(C=CC=1)C1=CC=CC=C1)C)C(=O)O RHAHNDIBVWTCNK-CVDCTZTESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QXJFQOALSRFDKT-MRXNPFEDSA-N (3R)-1-[[4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridin-2-yl]methyl]pyrrolidin-3-ol Chemical compound C1(C=2C(Cl)=C(NC3=C4C(SC(=N4)CN4C[C@@H](CC4)O)=CC=N3)C=CC=2)=CC=CC=C1 QXJFQOALSRFDKT-MRXNPFEDSA-N 0.000 description 1
- QXJFQOALSRFDKT-INIZCTEOSA-N (3S)-1-[[4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridin-2-yl]methyl]pyrrolidin-3-ol Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1N=C(S2)CN1C[C@H](CC1)O)C1=CC=CC=C1 QXJFQOALSRFDKT-INIZCTEOSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
- UJBDBOYWHDPFLK-WCCKRBBISA-N (5s)-5-(aminomethyl)pyrrolidin-2-one;hydrochloride Chemical compound Cl.NC[C@@H]1CCC(=O)N1 UJBDBOYWHDPFLK-WCCKRBBISA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IRPWVEBIMPXCAZ-UHFFFAOYSA-N 1,3-dibromo-2-chlorobenzene Chemical compound ClC1=C(Br)C=CC=C1Br IRPWVEBIMPXCAZ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- BULSRLAASYCZHJ-UHFFFAOYSA-N 2-(3-bromo-2-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound BrC=1C(=C(C=CC=1)B1OC(C(O1)(C)C)(C)C)Cl BULSRLAASYCZHJ-UHFFFAOYSA-N 0.000 description 1
- XLPSBJLZLLEBED-UHFFFAOYSA-N 2-(bromomethyl)-N-(2-chloro-3-phenylphenyl)-[1,3]thiazolo[4,5-c]pyridin-4-amine Chemical compound C1=C(C2=CC=CC=C2)C(Cl)=C(NC2=C3C(SC(=N3)CBr)=CC=N2)C=C1 XLPSBJLZLLEBED-UHFFFAOYSA-N 0.000 description 1
- ANJRXQNHTHWYEX-UHFFFAOYSA-N 2-(methoxymethyl)-5-oxido-[1,3]thiazolo[4,5-c]pyridin-5-ium Chemical compound COCC=1SC2=C(C=[N+](C=C2)[O-])N1 ANJRXQNHTHWYEX-UHFFFAOYSA-N 0.000 description 1
- XZSYDZFXDRUKLA-UHFFFAOYSA-N 2-(methoxymethyl)-[1,3]thiazolo[4,5-c]pyridine Chemical class COCC=1SC2=C(C=NC=C2)N=1 XZSYDZFXDRUKLA-UHFFFAOYSA-N 0.000 description 1
- CYXJWDIJMNIDEE-UHFFFAOYSA-N 2-[[4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridin-2-yl]methylamino]ethanol Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1N=C(S2)CNCCO)C1=CC=CC=C1 CYXJWDIJMNIDEE-UHFFFAOYSA-N 0.000 description 1
- LAUDTOPDHJTSJE-UHFFFAOYSA-N 2-[[4-[2-chloro-3-(2,3-dihydro-1,4-benzodioxin-6-yl)anilino]-[1,3]thiazolo[4,5-c]pyridin-2-yl]methylamino]ethanol Chemical compound C1(C=2C=C3OCCOC3=CC=2)=C(Cl)C(NC2=C3C(SC(=N3)CNCCO)=CC=N2)=CC=C1 LAUDTOPDHJTSJE-UHFFFAOYSA-N 0.000 description 1
- FTWISXQQQIUOSK-UHFFFAOYSA-N 2-[[4-[2-chloro-3-[3-(2-morpholin-4-ylethoxy)phenyl]anilino]-[1,3]thiazolo[4,5-c]pyridin-2-yl]methylamino]ethanol Chemical compound C=1(C=CC=C(C=1Cl)NC1=C2C(=CC=N1)SC(=N2)CNCCO)C1=CC(OCCN2CCOCC2)=CC=C1 FTWISXQQQIUOSK-UHFFFAOYSA-N 0.000 description 1
- SSDNQCYSBCNVPS-UHFFFAOYSA-N 2-[[4-[2-chloro-3-[3-(3-chloropropoxy)-2-methylphenyl]anilino]-[1,3]thiazolo[4,5-c]pyridin-2-yl]methylamino]ethanol Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1N=C(S2)CNCCO)C1=C(C(=CC=C1)OCCCCl)C SSDNQCYSBCNVPS-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- JYHSJQNYYLGMEI-UHFFFAOYSA-N 3,3-dimethoxypropanenitrile Chemical compound COC(OC)CC#N JYHSJQNYYLGMEI-UHFFFAOYSA-N 0.000 description 1
- DAISBANOWYIMMA-UHFFFAOYSA-N 3-(2-methyl-3-phenylanilino)thieno[3,2-b]pyridine-6-carbaldehyde Chemical compound C=1(C=CC=C(C=1C)NC1=CSC2=C1N=CC(C=O)=C2)C1=CC=CC=C1 DAISBANOWYIMMA-UHFFFAOYSA-N 0.000 description 1
- INBHBLBDUJSDDA-UHFFFAOYSA-N 3-(2-methyl-3-phenylanilino)thieno[3,2-b]pyridine-6-carbonitrile Chemical compound C=1(C=CC=C(C=1C)NC1=CSC2=C1N=CC(C#N)=C2)C1=CC=CC=C1 INBHBLBDUJSDDA-UHFFFAOYSA-N 0.000 description 1
- OIIBRAGQGFLUFI-UHFFFAOYSA-N 3-amino-1h-pyridin-4-one Chemical compound NC1=CNC=CC1=O OIIBRAGQGFLUFI-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- PSEUMNAPCMOENJ-UHFFFAOYSA-N 4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridine-2-carbaldehyde Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1N=C(S2)C=O)C1=CC=CC=C1 PSEUMNAPCMOENJ-UHFFFAOYSA-N 0.000 description 1
- FWWRBQHEPTYUBP-UHFFFAOYSA-N 4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[5,4-c]pyridine-2-carbaldehyde Chemical compound C=1(C=CC=C(C=1Cl)NC1=NC=CC2=C1SC(=N2)C=O)C1=CC=CC=C1 FWWRBQHEPTYUBP-UHFFFAOYSA-N 0.000 description 1
- JVNRVGDUGJSECM-UHFFFAOYSA-N 4-chloro-2-methylsulfanyl-[1,3]oxazolo[5,4-c]pyridine Chemical compound C1=NC(Cl)=C2OC(SC)=NC2=C1 JVNRVGDUGJSECM-UHFFFAOYSA-N 0.000 description 1
- IBLUUUWDTBKEIH-UHFFFAOYSA-N 6-(3-bromo-2-chlorophenyl)-2-methoxypyridine-3-carbaldehyde Chemical compound BrC=1C(=C(C=CC=1)C1=NC(=C(C=O)C=C1)OC)Cl IBLUUUWDTBKEIH-UHFFFAOYSA-N 0.000 description 1
- AVBARORPQMEWPR-UHFFFAOYSA-N 6-chloro-2-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC(Cl)=CC=C1C=O AVBARORPQMEWPR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- ZIMOLYFKVZKGNF-UHFFFAOYSA-N CC1=C(C=CC=C1B(O)O)C1=CC=CC=C1 Chemical compound CC1=C(C=CC=C1B(O)O)C1=CC=CC=C1 ZIMOLYFKVZKGNF-UHFFFAOYSA-N 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- ODKOXPSKHZKPRP-UHFFFAOYSA-N COCC(=O)Nc1c[nH]ccc1=O Chemical compound COCC(=O)Nc1c[nH]ccc1=O ODKOXPSKHZKPRP-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- RBBROEHDCBLERH-UHFFFAOYSA-N ClC1=C(C=CC=C1NC1=NC=CC2=C1OC(=N2)SC)C2=CC=CC=C2 Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1OC(=N2)SC)C2=CC=CC=C2 RBBROEHDCBLERH-UHFFFAOYSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SZDRDZKJTLPVND-UHFFFAOYSA-N N-(2-chloro-3-phenylphenyl)-2-(methoxymethyl)-[1,3]thiazolo[4,5-c]pyridin-4-amine Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1N=C(S2)COC)C1=CC=CC=C1 SZDRDZKJTLPVND-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KAOIHLTWGGVKPO-UHFFFAOYSA-N [4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridin-2-yl]methanol Chemical compound ClC1=C(C=CC=C1NC1=NC=CC2=C1N=C(S2)CO)C1=CC=CC=C1 KAOIHLTWGGVKPO-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RMIODHQZRUFFFF-UHFFFAOYSA-N methoxyacetic acid Chemical compound COCC(O)=O RMIODHQZRUFFFF-UHFFFAOYSA-N 0.000 description 1
- CLPSCJQCSDGEES-LPHOPBHVSA-N methyl (2S,4S)-1-[[4-(2-chloro-3-phenylanilino)-[1,3]thiazolo[4,5-c]pyridin-2-yl]methyl]-4-hydroxypyrrolidine-2-carboxylate Chemical compound C1=C(C2=CC=CC=C2)C(Cl)=C(NC2=NC=CC3=C2N=C(S3)CN2[C@@H](C[C@@H](C2)O)C(=O)OC)C=C1 CLPSCJQCSDGEES-LPHOPBHVSA-N 0.000 description 1
- KLGSHNXEUZOKHH-FHAQVOQBSA-N methyl (2s,4s)-4-hydroxypyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1C[C@H](O)CN1 KLGSHNXEUZOKHH-FHAQVOQBSA-N 0.000 description 1
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- FOXHAHBHIMREKV-FXRZFVDSSA-M sodium;(e)-2-cyano-3,3-dimethoxyprop-1-en-1-olate Chemical compound [Na+].COC(OC)C(=C\[O-])\C#N FOXHAHBHIMREKV-FXRZFVDSSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- AGZYNVVJQAOVRP-UHFFFAOYSA-N thiophene-3,4-diamine Chemical compound NC1=CSC=C1N AGZYNVVJQAOVRP-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有免疫调节作用的芳香化合物的制备方法和用途。具体地,本发明公开了结构如式I所示的化合物,其中,各基团的定义如说明书中所述。本发明还提供了该类化合物在调节免疫,抑制PD‑1/PD‑L1方面的用途。
Description
技术领域
本发明涉及小分子蛋白抑制剂领域,具体地,本发明提供了一种具有免疫调节功能的化合物的制备和应用。
背景技术
免疫系统具有监视、防御、调控等作用。细胞免疫主要参与对胞内寄生的病原微生物的免疫应答及对肿瘤细胞的免疫应答,参与迟发型变态反应和自身免疫病的形成,参与移植排斥反应及对体液免疫的调节。T淋巴细胞被抗原递呈细胞的激活通常受两种不同信号的调节。初级信号由APC细胞上的主要组织相容性复合体(MHC)呈递外来抗原肽通过T细胞受体(TCR)转导。次级信号,又称共刺激信号,通过APC细胞上的共刺激分子与T细胞表面受体结合,传递给T细胞,调节T细胞增殖,细胞因子分泌和效应功能。次级信号包括正调节和负调节两种方式,正信号促进T细胞激活,负信号诱导T细胞耐受,对人体适应和调整自身免疫细胞对外界不同抗原的反应作用至关重要。
程序性细胞死亡蛋白配体1(Programmed death-ligand 1,PD-L1),又可称为分化簇274(cluster of differentiation 274,CD274)或者B7同源蛋白1(B7homolog1,B7-H1),属于肿瘤坏死因子超家族,是由290个氨基酸残基组成的I型跨膜糖蛋白,包含一个IgV样区、一个IgC样区、一个跨膜疏水区和一个30个氨基酸的胞内尾部,完整分子量为40kDa。PD-L1mRNA在几乎所有组织中都有表达,但PD-L1蛋白只在少部分组织中持续表达,包括肝脏、肺脏、扁桃体以及免疫特赦组织如眼、胎盘等。PD-L1也表达于活化的T细胞,B细胞,单核细胞,树突状细胞,巨噬细胞等。
PD-L1的受体为PD-1,主要表达于活化的CD4+T细胞、CD8+T细胞、NK细胞、B细胞和活化的单核细胞等免疫细胞表面。PD-L1与PD-1结合可以启动PD-1胞浆区ITIM(免疫受体酪氨酸抑制作用模块)酪氨酸残基的磷酸化,促使酪氨酸磷脂酶与SHP2结合,活化SHP2,使下游Syk和PI3K发生去磷酸化从而传递终止信号,限制抗原呈递细胞或者树突状细胞与T细胞的相互作用。这种结合还可以进一步抑制T细胞的代谢,抑制抗凋亡蛋白Bcl-2的分泌,减少效应细胞因子IL-2,IFN-γ的分泌,诱导T细胞耗竭和凋亡,从而降低免疫T细胞参与的免疫应答,行使负性调节功能。
T细胞识别抗原并活化后会分泌IFN-γ。T细胞来源的IFN-γ会扩增和维持T细胞功能,比如上调MHC分子,增强目标细胞的抗原处理和呈递,促进T细胞分化。IFN-γ同时也会诱导免疫炎症部位组织的PD-L1表达,防止过度免疫对组织造成伤害。IFN-γ可以诱导常规上皮细胞,血管内皮细胞,髓样细胞,幼稚T细胞等细胞表面PD-L1的表达。IFN-γ诱导产生的干扰素调节因子1(IRF-1)也可以与PD-L1转录起始位点前200bp和320bp处的干扰素调节因子结合位点结合,从转录水平调节PD-L1。PD-L1可以与T细胞表面的PD-1结合行使负调节功能,从而保护炎性部位。
PD-L1的负性调控功能在肿瘤免疫中发挥着重要作用。2004年,Konishi等率先在非小细胞肺癌病人的组织样本中发现PD-L1的表达,随后PD-L1被发现表达于各种肿瘤病人的组织中,包括胃癌,肺癌,肝癌,肝内胆管癌,结肠癌,胰腺癌,卵巢癌,乳腺癌,子宫颈癌,头颈鳞状细胞癌,鼻咽癌,食管癌,膀胱癌,肾细胞癌,皮肤癌,口腔鳞状细胞癌等。细胞恶变过程中,由于基因突变、外源基因(病毒)表达或静止基因激活等原因会产生新的蛋白分子,这些蛋白质在细胞内降解后,某些降解的肽段可以表达于细胞表面,成为肿瘤抗原。免疫系统可以通过免疫监察识别肿瘤抗原并清除肿瘤细胞,而肿瘤细胞则利用PD-L1逃避免疫攻击。
肿瘤部位PD-L1的表达可以通过多种途径保护肿瘤细胞免受伤害。肿瘤浸润淋巴细胞(TIL)分泌IFN-γ可诱导肿瘤细胞及周围基质细胞表达PD-L1。而肿瘤细胞的PD-L1可以与TIL上PD-1结合,抑制TIL细胞的活化,并进一步导致其凋亡。体外实验证明,肿瘤细胞相关PD-L1可以增加肿瘤特异T细胞的调亡,而PD-L1单克隆抗体可以减弱这种作用。肿瘤相关PD-L1可以促进T细胞表达IL-10,进一步抑制免疫反应。PD-L1不仅仅是PD-1的配体,他也可以作为受体传递反向的信号保护肿瘤细胞免受FAS-FASL等其他抗肿瘤途径诱导的凋亡。
目前多个已上市的靶向PD-1或者PD-L1的单克隆抗体药物证实PD-1/PD-L1的阻断剂可用于多种肿瘤的临床治疗。然而抗体药物有其自身的特点,如生产成本高,稳定性较差,需经注射给药及易产生免疫原性等。而小分子药物具有组织渗透性好,储存运输方便,生产成本较低,无免疫原性及通常可口服给药等优势,因此研究开发PD-1/PD-L1的小分子阻断剂具有显著的应用价值和社会价值。
综上所述,本领域迫切需要开发小分子的PD-1/PD-L1阻断剂。
发明内容
本发明的目的是提供一种小分子的PD-1/PD-L1阻断剂。
本发明的第一方面,提供了一种如下式I所示的化合物,其立体异构体或其互变异构体,或其药学上可接受的盐、水合物或溶剂化物:
其中,
M选自O或NH;
X2选自下组:N、NR3、CR3、O、S、N=CR3、CR3=N或CR3=CR3;
X4选自下组:N、NR3、CH、O、S、N=CH、CH=N或CH=CH;
且X2和X4中有且仅有一个为选自下组的基团:CR3=CR3、N=CR3、或CR3=N(在X4中R3为H);
X1和X5各自独立地选自下组:N、CH、O或S;
X3选自下组:N、CR3、O或S;
且X3或X4中至少一个为O、S或N;
Y1和Y2各自独立地为N或C;
Z1、Z2和Z3各自独立地为N或CR4;
R1选自下组:H、卤素、CN、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基;
R2选自下组:取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂芳基、或取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂环基;且所述的R2基团上有一个或多个氢原子被R5取代;
Ra和Rb各自独立地选自下组:H、-(C=O)-取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C8烷胺基、取代或未取代的C1-C8烷氧基、取代或未取代的C3-C10环烷基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的3-10元杂环烷基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基、或取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂环基;
或所述的Ra和Rb与相邻的N原子共同构成取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂环基;
所述的R4选自下组:H、卤素、CN、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基;
所述的R5选自下组:H、CN、卤素、取代或未取代的(-L1-L2-(C1-C8亚烷基)-(取代或未取代的5-7元杂芳基))、取代或未取代的(-L1-L2-(C1-C8亚烷基)-N(Ra)(Rb))、-O-取代或未取代的(-(C1-C8亚烷基)-O-(C1-C8亚烷基)-N(Ra)(Rb))、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基、取代或未取代的(-L1-L2-5-10元杂芳基-(C1-C8亚烷基)-N(Ra)(Rb));其中,所述的L1和L2各自独立地选自下组:无、取代或未取代的C1-C8亚烷基、-NH-C(=O)-NH-、-C(=O)-NH-、-O-、-S-或-NH-;或两个R5与相连的碳原子共同构成选自下组的基团:取代或未取代的5-7元杂芳基、取代或未取代的5-7元杂环基;
除非特别说明,所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代:卤素、C1-C6烷氧基、卤代的C1-C6烷氧基、C3-C8环烷基、卤代的C3-C8环烷基、甲基砜基、-S(=O)2NH2、氧代(=O)、-CN、羟基、-NH2、C1-C6胺基、羧基、C1-C6酰胺基(-C(=O)-N(Rc)2或-NH-C(=O)(Rc),Rc为H或C1-C5的烷基)、或取代或未取代的选自下组的基团:C1-C6烷基、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的5-10元杂环基(包括并环、螺环)、-(CH2)-C6-C10芳基、-(CH2)-(具有1-3个选自N、S和O的杂原子的5-10元杂芳基),且所述的取代基选自下组:卤素、C1-C6烷基、C1-C6烷氧基、氧代、-CN、-OH、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基;
附加条件是式I化合物为化学上稳定的结构。
在另一优选例中,所述的R2为选自下组的基团:取代或未取代的苯基。
在另一优选例中,所述的化合物具有如下式II所示的结构:
在另一优选例中,所述的化合物具有如下式II所示的结构:
所述的R5'选自下组:H、CN、卤素;
R6为(C1-C8亚烷基)-N(Ra)(Rb);
M环选自下组:取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基;
p为1、2、3或4。
在另一优选例中,所述的式I化合物具有如下式所示的结构:
X为CH或N;
R为选自下组的取代基:卤素、CN、C1-C6烷基、卤代的C1-C6烷基、C1-C6烷氧基。
在另一优选例中,所述的Z1、Z2和Z3各自独立地为CR4。
在另一优选例中,所述的Z1、Z2和Z3各自独立地为CH。
在另一优选例中,所述的-N(Ra)Rb选自下组:
在另一优选例中,所述的R5选自下组:H、Me、Cl、CN、-O(CH2)n-(取代或未取代的5-7元杂芳环)、-O(CH2)n-N(Ra)(Rb)。
在另一优选例中,所述的R5选自下组:H、Me、Cl、CN,或选自下组的基团:
其中,n=1-2。
在另一优选例中,所述的R6选自下组:
在另一优选例中,所述的式I化合物选自下组:
在另一优选例中,所述的式I化合物选自下组:
本发明的第二方面,提供了一种药物组合物,所述的药物组合物包含(1)如本发明第一方面所述的化合物,或其立体异构体或互变异构体,或其药学上可接受的盐、水合物或溶剂化物;(2)药学上可接受的载体。
本发明的第三方面,提供了一种如本发明第一方面所述的化合物或其立体异构体或互变异构体,或其药学上可接受的盐、水合物或溶剂化物,或如本发明第二方面所述的药物组合物用于制备预防和/或治疗与PD-1/PD-L1的活性或表达量相关的疾病的药物组合物的用途。
在另一优选例中,所述的疾病选自下组:肿瘤、病原体感染、自身免疫应答相关疾病。
在另一优选例中,所述的药物组合物用于选自下组的疾病的治疗:黑素瘤(例如转移性恶性黑素瘤)、肾癌(例如透明细胞癌)、前列腺癌(例如激素不应性前列腺腺癌)、乳癌、结肠癌和肺癌(例如非小细胞肺癌)。骨癌、胰腺癌、皮肤癌、头或颈癌、皮肤或眼内恶性黑素瘤、子宫癌、卵巢癌、直肠癌、肛区癌、胃肠、睾丸癌、子宫癌、输卵管癌、子宫内膜癌、宫颈癌、阴道癌、阴户癌、何杰金氏病、非何杰金氏淋巴瘤、食道癌、小肠癌、内分泌系统的癌症、甲状腺癌、曱状旁腺癌、肾上腺癌、软組织肉瘤、尿道癌、阴茎癌、慢性或急性白血病(包括急性髓细胞样白血病、慢性髓细胞样白血病、急性成淋巴细胞性白血病、慢性淋巴细胞性白血病)、儿童期实体瘤、淋巴细胞性淋巴瘤、膀胱癌、肾或输尿管癌、肾盂癌、中枢神经系统(CNS)的赘生物/肿瘤、原发性CNS淋巴瘤、肿瘤血管发生、脊髓轴(spinalaxis)肿瘤、脑干胶质瘤、垂体腺瘤、卡波西氏(Kaposi)肉瘤、表皮样癌、鳞状细胞癌、T细胞淋巴瘤、环境诱发的癌症(包括由石棉诱发的那些癌症)、及所述癌症的组合。转移性癌症,尤其是表达PD-Ll的转移性癌症
在另一优选例中,所述的药物组合物用于联合用药方案,较佳地,所述的联合用药方案包括:联合肿瘤化疗方案,其他肿瘤免疫治疗剂(小分子化合物及抗体等),放疗方案,肿瘤靶向药,肿瘤疫苗(如人类乳头瘤病毒(HPV)、肝炎病毒(HBV和HCV)和卡波西疱疹肉瘤病毒(KHSV))。
在另一优选例中,所述的药物组合物用于单独或联合使用用于治疗暴露于特定毒素或病原体的患者的治疗。其中包括但不限于各种病毒,病原体细菌,病原体真菌,病原体寄生虫等的治疗。如HIV、肝炎病毒(甲、乙、丙)、流感病毒、疱疹病毒、贾第虫、疟疾、利什曼原虫、金黄色葡萄球菌、绿脓杆菌等病原体已建立的感染。
在另一优选例中,所述的药物组合物用于诱导治疗性自身免疫应答。
在另一优选例中,所述的药物组合物用于治疗具有不恰当的其他自身抗原积累的患者,如淀粉状蛋白沉积物,包括阿尔茨海默病中的Αβ、细胞因子如TNFa和IgE。
本发明的第四方面,提供了一种PD-1/PD-L1抑制剂,所述抑制剂包含本发明第一方面所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物或溶剂化物。
应理解,在本发明范围内中,本发明的上述各技术特征和在下文(如实施例)中具体描述的各技术特征之间都可以互相组合,从而构成新的或优选的技术方案。限于篇幅,在此不再一一累述。
具体实施方式
本发明人经过长期而深入的研究,设计并合成了一类新型PD-1小分子抑制剂。在此基础上,发明人完成了本发明。
术语
除非另外定义,否则本文中所用的全部技术与科学术语均具有如本发明所属领域的普通技术人员通常理解的相同含义。
如本文所用,在提到具体列举的数值中使用时,术语“约”意指该值可以从列举的值变动不多于1%。例如,如本文所用,表述“约100”包括99和101和之间的全部值(例如,99.1、99.2、99.3、99.4等)。
如本文所用,术语“含有”或“包括(包含)”可以是开放式、半封闭式和封闭式的。换言之,所述术语也包括“基本上由…构成”、或“由…构成”。
定义
如本文所用,术语“烷基”包括直链或支链的烷基。例如C1-C8烷基表示具有1-8个碳原子的直链或支链的烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基等。
如本文所用,术语“烯基”包括直链或支链的烯基。例如C2-C6烯基指具有2-6个碳原子的直链或支链的烯基,例如乙烯基、烯丙基、1-丙烯基、异丙烯基、1-丁烯基、2-丁烯基、或类似基团。
如本文所用,术语“炔基”包括直链或支链的炔基。例如C2-C6炔基是指具有2-6个碳原子的直链或支链的炔基,例如乙炔基、丙炔基、丁炔基、或类似基团。
如本文所用,术语“C3-C8环烷基”指具有3-8个碳原子的环烷基。其可以是单环,例如环丙基、环丁基、环戊基、环己基、或类似基团。也可以是双环形式,例如桥环或螺环形式。
如本文所用,术语“C1-C8烷氧基”是指具有1-8个碳原子的直链或支链的烷氧基;例如,甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔丁氧基等。
如本文所用,术语“具有1-3个选自下组N、S和O的杂原子的3-10元杂环烷基”是指具有3-10个原子的且其中1-3个原子为选自下组N、S和O的杂原子的饱和或部分饱和的环状基团。其可以是单环,也可以是双环形式,例如桥环或螺环形式。具体的实例可以为氧杂环丁烷、氮杂环丁烷、四氢-2H-吡喃基、哌啶基、四氢呋喃基、吗啉基和吡咯烷基等。
如本文所用,术语“C6-C10芳基”是指具有6-10个碳原子的芳基,例如,苯基或萘基等类似基团。
如本文所用,术语“具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基”指具有5-10个原子的且其中1-3个原子为选自下组N、S和O的杂原子的环状芳香基团。其可以是单环,也可以是稠环形式。具体的实例可以为吡啶基、哒嗪基、嘧啶基、吡嗪基、三嗪基、吡咯基、吡唑基、咪唑基、(1,2,3)-三唑基以及(1,2,4)-三唑基、四唑基、呋喃基、噻吩基、异恶唑基、噻唑基、恶唑基等。
除非特别说明,否则本发明的基团均可被选自下组的取代基所取代:卤素、腈基、硝基、羟基、氨基、C1-C6烷基-胺基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、卤代C1-C6烷基、卤代C2-C6烯基、卤代C2-C6炔基、卤代C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基-羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基等。
如本文所用,“卤素”或“卤原子”指F、Cl、Br、和I。更佳地,卤素或卤原子选自F、Cl和Br。“卤代的”是指被选自F、Cl、Br、和I的原子所取代。
除非特别说明,本发明所描述的结构式意在包括所有的同分异构形式(如对映异构,非对映异构和几何异构体(或构象异构体)):例如含有不对称中心的R、S构型,双键的(Z)、(E)异构体等。因此,本发明化合物的单个立体化学异构体或其对映异构体、非对映异构体或几何异构体(或构象异构体)的混合物都属于本发明的范围。
如本文所用,术语“互变异构体”表示具有不同能量的结构同分异构体可以超过低能垒,从而互相转化。比如,质子互变异构体(即质子移变)包括通过质子迁移进行互变,如1H-吲唑与2H-吲唑。化合价互变异构体包括通过一些成键电子重组而进行互变。
如本文所用,术语“溶剂合物”是指本发明化合物与溶剂分子配位形成特定比例的配合物。
式I化合物
本发明提供了一种如下式I所示的化合物,其立体异构体或其互变异构体,或其药学上可接受的盐、水合物或溶剂化物:
其中,
X2和X4各自独立地选自下组:N、NR3、CR3、O、S、N=CR3、CR3=N或CR3=CR3,且X2和X4中有且仅有一个为选自下组的基团:CR3=CR3、N=CR3、或CR3=N;
X1、X3和X5各自独立地选自下组:N、CR3、O或S;
且X3或X4中至少一个为O、S或N;
Y1和Y2各自独立地为N或C;
Z1、Z2和Z3各自独立地为N或CR4;
R1选自下组:H、卤素、CN、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基;
R2选自下组:取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂芳基、或取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂环基;且所述的R2基团上有一个或多个氢原子被R5取代;
Ra和Rb各自独立地选自下组:H、羧基、-(C=O)-取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C8烷胺基、取代或未取代的C1-C8烷氧基、取代或未取代的C3-C10环烷基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的3-10元杂环烷基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基、或取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂环基;
或所述的Ra和Rb与相邻的N原子共同构成取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂环基;
所述的R4选自下组:H、卤素、CN、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基;
所述的R5选自下组:H、CN、卤素、取代或未取代的-L1-L2-(C1-C8亚烷基)-(取代或未取代的5-7元杂芳基)、取代或未取代的-L1-L2-(C1-C8亚烷基)-N(Ra)(Rb)、-O-取代或未取代的-(C1-C8亚烷基)-O-(C1-C8亚烷基)-N(Ra)(Rb);其中,所述的L1和L2各自独立地选自下组:无、取代或未取代的C1-C8亚烷基、-NH-C(=O)-NH-、-C(=O)-NH-、-O-、-S-或-NH-;或两个R5与相连的碳原子共同构成选自下组的基团:取代或未取代的5-7元杂芳基、取代或未取代的5-7元杂环基;
除非特别说明,所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代:卤素、C1-C6烷氧基、卤代的C1-C6烷氧基、C3-C8环烷基、卤代的C3-C8环烷基、甲基砜基、-S(=O)2NH2、氧代(=O)、-CN、羟基、-NH2、C1-C6胺基、羧基、C1-C6酰胺基(-C(=O)-N(Rc)2或-NH-C(=O)(Rc),Rc为H或C1-C5的烷基)、或取代或未取代的选自下组的基团:C1-C6烷基、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、-(CH2)-C6-C10芳基、-(CH2)-(具有1-3个选自N、S和O的杂原子的5-10元杂芳基),且所述的取代基选自下组:卤素、C1-C6烷基、C1-C6烷氧基、氧代、-CN、-OH、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基;
附加条件是式I化合物为化学上稳定的结构。
优选的式I化合物为本申请实施例中所示的具体化合物。
式I化合物的制备
本发明还提供了一种制备如本发明第一方面所述化合物的方法,包括步骤:在适当的溶剂中,化合物1经取代反应得到化合物2,化合物2和化合物3在钯催化剂作用下,在碱和膦化合物存在下,反应得到化合物4,化合物4经还原得到化合物5,化合物5再经过还原胺化反应得到式6所示化合物。
药物组合物和施用方法
由于本发明化合物具有优异的PD-1的抑制活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物可用于预防和/或治疗与PD-1/PD-L1信号通路相关的疾病(例如,癌症)。
本发明的药物组合物包含安全有效量范围内的本发明化合物及药学上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明化合物/剂,更佳地,含有10-200mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、肠胃外(静脉内、肌肉内或皮下)。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
本发明化合物可以单独给药,或者与其他药学上可接受的化合物联合给药。
联合给药时,所述药物组合物还包括与一种或多种其他药学上可接受的化合物。该其他药学上可接受的化合物中的一种或多种可与本发明的化合物同时、分开或顺序地给药。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选20~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
在本发明的优选实施方式中,所述的药物组合物可以用于:
(1)用于治疗各种肿瘤,包括但不限制于黑素瘤(例如转移性恶性黑素瘤)、肾癌(例如透明细胞癌)、前列腺癌(例如激素不应性前列腺腺癌)、乳癌、结肠癌和肺癌(例如非小细胞肺癌)。骨癌、胰腺癌、皮肤癌、头或颈癌、皮肤或眼内恶性黑素瘤、子宫癌、卵巢癌、直肠癌、肛区癌、胃肠、睾丸癌、子宫癌、输卵管癌、子宫内膜癌、宫颈癌、阴道癌、阴户癌、何杰金氏病、非何杰金氏淋巴瘤、食道癌、小肠癌、内分泌系统的癌症、甲状腺癌、曱状旁腺癌、肾上腺癌、软組织肉瘤、尿道癌、阴茎癌、慢性或急性白血病(包括急性髓细胞样白血病、慢性髓细胞样白血病、急性成淋巴细胞性白血病、慢性淋巴细胞性白血病)、儿童期实体瘤、淋巴细胞性淋巴瘤、膀胱癌、肾或输尿管癌、肾盂癌、中枢神经系统(CNS)的赘生物/肿瘤、原发性CNS淋巴瘤、肿瘤血管发生、脊髓轴(spinalaxis)肿瘤、脑干胶质瘤、垂体腺瘤、卡波西氏(Kaposi)肉瘤、表皮样癌、鳞状细胞癌、T细胞淋巴瘤、环境诱发的癌症(包括由石棉诱发的那些癌症)、及所述癌症的组合。转移性癌症,尤其是表达PD-Ll的转移性癌症
(2)用于联合用药方案,例如联合肿瘤化疗方案,其他肿瘤免疫治疗剂(小分子化合物及抗体等),放疗方案,肿瘤靶向药,肿瘤疫苗等,如人类乳头瘤病毒(HPV)、肝炎病毒(HBV和HCV)和卡波西疱疹肉瘤病毒(KHSV)。可以在所述药剂之前、之后或同时施用,或者可以与其它已知疗法共施用。
(3)用于单独或联合使用用于治疗暴露于特定毒素或病原体的患者的治疗。其中包括但不限于各种病毒,病原体细菌,病原体真菌,病原体寄生虫等的治疗。如HIV、肝炎病毒(甲、乙、丙)、流感病毒、疱疹病毒、贾第虫、疟疾、利什曼原虫、金黄色葡萄球菌、绿脓杆菌等病原体已建立的感染。
(4)用于诱导治疗性自身免疫应答,以治疗具有不恰当的其他自身抗原积累的患者,如淀粉状蛋白沉积物,包括阿尔茨海默病中的Αβ、细胞因子如TNFa和IgE。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数按重量计算。
各实施例中:
分析方法I
LCMS仪器:Agilent 6110,UV检测器:G1315D
层析柱:Xbridge C18 3.0×50mm,2.5uM,柱温30℃
流动相:A:H2O(0.05%TFA),B:乙腈,梯度洗脱:0-1min 10%B,1-8min 10-95%B,9min 95%B
中间体A的合成:
3-氨基噻吩并[3,2-b]吡啶-6-甲腈
(E)-2-氰基-3,3-二甲氧基丙-1-烯-1-醇酸钠
在氢化钠(2.08g,52.1mmol)的乙醚(100mL)混合液中,依次加入化合物3,3-二甲氧基丙腈(5g,43.4mmol)和甲酸乙酯(6.43g,86.8mmol),反应混合物在室温下搅拌两天,过滤,固体用乙醚洗涤三次,烘干得到目标化合物(5g,70%)。
3-氨基噻吩并[3,2-b]吡啶-6-甲腈
在化合物A1(0.3g,1.8mmol)的甲醇(20mL)溶液中加入浓盐酸(0.3mL,12N),室温下搅拌10分钟后再加入噻吩-3,4-二胺(0.3g,1.8mmol)的甲醇(10mL)溶液,反应混合物在80度下搅拌2小时后,旋干,粗品用高效液相制备纯化得到白色固体目标化合物(100mg,30%)。
MS-ESI:m/z 176.0[M+H]+。
1H NMR(400MHz,CDCl3):δ8.96(s,1H),8.78(s,1H),7.44(s,1H)。
中间体B的合成:
4-氯-2-(甲氧基甲基)噻唑并[4,5-c]吡啶
N-(4-羟基吡啶-3-基)-2-甲氧基乙酰胺
室温下向化合物2-甲氧基乙酸(9.8g,109.1mmol)的二氯甲烷(30mL)溶液中滴加草酰氯(218.2mmol,18.4mL),N,N-二甲基甲酰胺(0.1mL),反应2小时后浓缩,粗品溶于二氯甲烷(10mL)中,然后将此溶液于室温下滴加入3-氨基吡啶-4-酚(8.0g,4.54mmol),二异丙胺(38.5mL,218.1mmol)的二氯甲烷(100ml)混合液中,加热回流2小时后室温搅拌过夜,浓缩,粗品用硅胶柱纯化(二氯甲烷/甲醇=20/1)得到白色固体目标化合物(3.1g,23%)。
1H NMR(400MHz,CDCl3):δ11.51(brs,1H),9.18(s,1H),8.68(s,1H),7.68(dd,J=7.2,0.8Hz,1H),6.25(d,J=7.2Hz,1H),4.16(s,2H),3.41(s,3H)。
2-(甲氧基甲基)噻唑并[4,5-c]吡啶
室温下向化合物B1(3.1g,17.0mmol)的吡啶(30ml)溶液中加入五硫化二磷(4.5g,20.4mmol),然后加热至110℃反应3小时,浓缩,粗品溶于乙酸乙酯中,用饱和食盐水洗涤,无水硫酸钠干燥,过滤,浓缩后粗品用硅胶柱层析纯化(石油醚/乙酸乙酯=10/1-3/1洗脱)得黄色固体目标化合物(700mg,22%)。
1H NMR(400MHz,CDCl3):δ9.30(s,1H),8.53(d,J=5.6Hz,1H),7.87(dd,J=7.2,0.8Hz,1H),4.89(s,2H),3.57(s,3H)。
2-(甲氧基甲基)噻唑并[4,5-c]吡啶5-氧化
室温下向化合物B2(760mg,4.22mmol)的二氯甲烷(10mL)溶液中分批加入间氯过氧苯甲酸(1.14g,4.64mmol),室温反应过夜,浓缩,粗品用硅胶柱层析纯化(二氯甲烷/甲醇=20/1洗脱)得黄色固体目标化合物(800mg,96%)。
MS(ESI):m/z=197.1[M+H]+。
4-氯-2-(甲氧基甲基)噻唑并[4,5-c]吡啶
室温下将化合物B3(800mg,4.08mmol)分批加入到三氯氧磷(10mL)中,然后升温至100℃反应1小时,浓缩旋干,粗品溶于乙酸乙酯中,依次用饱和碳酸氢钠溶液和饱和食盐水洗涤,无水硫酸钠干燥,粗品用硅胶柱层析纯化(石油醚/乙酸乙酯=30/1-10/1洗脱)得黄色固体目标化合物(600mg,69%)。
MS(ESI):m/z=215.2[M+H]+。
1H NMR(400MHz,CDCl3):δ8.31(d,J=5.6Hz,1H),7.80(d,J=5.6Hz,1H),4.92(s,2H),3.59(s,3H)。
中间体C的合成:
6-(2-氯-3-(4,4,5,5-四甲基-1,3,2-二噁硼戊环-2-基)苯基)-2-甲氧基尼古丁醛
2-(3-溴-2-氯-苯基)-4,4,5,5-四甲基-[1,3,2]二噁硼戊环
往1,3-二溴-2-氯苯(5g,18.52mmol)的1,4-二氧六环(200mL)溶液中加入1,1'-二(二苯膦基)二茂铁二氯化钯(II)(678mg,0.93mmol),联硼酸频那醇酯(4.7g,18.52mmol),醋酸钾(5.44g,55.56mmol)。混合物在氮气球保护下90摄氏度搅拌过夜。反应液冷却后倒入水中(200mL),用乙酸乙酯(200mL*3)萃取。有机相用无水硫酸钠干燥,抽滤,浓缩。残留物通过正相硅胶层析柱(石油醚:乙酸乙酯=100:1)纯化得到白色固体目标化合物C1(2.7g,46%)。
1HNMR(400 MHz,CDCl3):δ7.67-7.65(m,1H),7.60-7.58(m,1H),7.11-7.07(m,1H),1.36(s,12H).
6-(3-溴-2-氯苯基)-2-甲氧基尼古丁醛
将C1(1.71g,5.39mmol),6-氯-2-甲氧基吡啶-3-甲醛(1.02g,5.93mmol),四-三苯基膦钯(312mg,0.27mmol),1,4-二氧六环(27mL),水(2.7mL),碳酸钾(1.49g,10.77mmol)的混合物在氮气球保护下95摄氏度搅拌3小时。反应液冷却至室温后用二氯甲烷(100mL)稀释,然后用水(50mL)和饱和食盐水(50mL)洗涤。有机相用无水硫酸钠干燥,抽滤,浓缩。残留物通过正相硅胶层析柱(石油醚:乙酸乙酯=100:1)纯化得到白色固体目标化合物C2(1.24g,70%)。
1HNMR(400MHz,CDCl3):δ10.41(s,1H),8.20-8.18(m,1H),7.73-7.71(m,1H),7.52-7.50(m,1H),7.30-7.22(m,2H),4.10(s,3H).
6-(2-氯-3-(4,4,5,5-四甲基-1,3,2-二噁硼戊环-2-基)苯基)-2-甲氧基尼古丁醛
往C2(720mg,2.2mmol)的1,4-二氧六环(20mL)溶液中加入1,1'-二(二苯膦基)二茂铁二氯化钯(II)(161mg,0.22mmol),联硼酸频那醇酯(616mg,2.43mmol),醋酸钾(606mg,6.17mmol)。混合物在氮气球保护下95摄氏度搅拌过夜。反应液冷却后倒入水中(50mL),用乙酸乙酯(50mL*3)萃取。有机相用无水硫酸钠干燥,抽滤,浓缩。残留物通过正相硅胶层析柱(石油醚:乙酸乙酯=100:1)纯化得到白色固体目标化合物C(500mg,46%)。
1HNMR(400MHz,CDCl3):δ10.41(s,1H),8.16(d,J=8Hz,1H)7.72-7.70(m,1H),7.62-7.60(m,1H),7.37-7.31(m,2H),4.09(s,3H),1.37(s,12H).
实施例1:
2-(((3-((2-甲基-[1,1’-联苯基]-3-基)氨基)噻吩并[3,2-b]吡啶-6-基)甲基)氨基)乙烷-1-醇
3-((2-甲基-[1,1’-联苯基]-3-基)氨基)噻吩并[3,2-b]吡啶-6-甲腈.
向中间体A(65mg,0.37mmol),(2-甲基-[1,1’-联苯基]-3-基)硼酸(157mg,0.74mmol)的二氯甲烷(5mL)溶液中加入醋酸铜(67mg,0.37mmol)和三乙胺(75mg,0.74mmol),反应液在室温下敞口搅拌16小时;反应液浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=1.5/1)得到目标化合物1A(28mg,22%),为黄色固体。
MS(ESI):m/z=342.1[M+H]+。
3-((2-甲基-[1,1’-联苯基]-3-基)氨基)噻吩并[3,2-b]吡啶-6-甲醛
在冰浴下向化合物1A(28mg,0.08mmol)的无水二氯甲烷(4mL)溶液中滴入二异丁基氢化铝(0.1mL,0.10mmol,1M的甲苯溶液)。反应液自然升至室温共搅拌1小时;TLC显示原料完全消失,反应液在冰浴下加水淬灭,粗品通过正相快速分离纯化(石油醚/乙酸乙酯=1/1)得到目标化合物1B(20mg,74%),为黄色固体。
MS(ESI):m/z=345.1[M+H]+。
2-(((3-((2-甲基-[1,1’-联苯基]-3-基)氨基)噻吩并[3,2-b]吡啶-6-基)甲基)氨基)乙烷-1-醇
向化合物1B(20mg,0.060mmol),2-氨基乙烷-1-醇(11mg,0.18mmol)的二氯甲烷(3mL)溶液中加入催化量的醋酸(1滴),反应液室温搅拌2小时后加入三乙酰氧基硼氢化钠(64mg,0.30mmol),反应液继续搅拌过夜;反应液浓缩,粗品通过制备型高效液相色谱纯化获得目标化合物(6.8mg,30%),为白色固体。
MS(ESI):m/z=390.3[M+H]+。
1H NMR(400MHz,MeOH-d4)δ8.63(s,1H),8.30(s,1H),7.47-7.28(m,6H),7.22-7.20(m,1H),7.00(s,1H),6.86(d,J=7.4Hz,1H),3.98(s,2H),3.68(t,J=5.6Hz,2H),2.77(t,J=5.6Hz,2H),2.21(s,3H)。
实施例2
(2S,4S)-4-羟基-1-((3-((2-甲基-[1,1’-联苯基]-3-基)氨基)噻吩并[3,2-b]吡啶-6-基)甲基)吡咯烷-2-羧酸
目标化合物在类似于实施例5的条件下制备自化合物1B和(2S,4S)-4-羟基吡咯烷-2-羧酸。
MS(ESI):m/z=460.2[M+H]+。
1H NMR(400MHz,MeOH-d4)δ8.75(s,1H),8.47(s,1H),8.42(s,1H),7.45-7.37(m,3H),7.35-7.28(m,3H),7.22-7.20(m,1H),7.07(s,1H),6.87(dd,J=7.7,1.2Hz,1H),4.51-4.36(m,3H),3.88-3.80(m,1H),3.47-3.39(m,1H),3.23-3.16(m,1H),2.68-2.57(m,1H),2.19(s,3H),2.16-2.06(m,1H)。
实施例3
2-(((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)氨基)乙酰胺
N-(2-氯-[1,1’-联苯基]-3-基)-2-(甲氧基甲基)噻唑并[4,5-c]吡啶-4-胺
将中间体B(500mg,2.33mmol),2-氯-[1,1’-联苯基]-3-胺(312mg,1.55mmol)和对甲苯磺酸一水合物(444mg,2.33mmol)的异丙醇(8mL)的溶液,在微波反应器中,加热到170℃并搅拌一个小时;反应液用乙酸乙酯稀释,饱和的碳酸氢钠水溶液洗涤两次,有机相浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=10/1)到得标题化合物(300mg,51%),为白色固体。
MS(ESI):m/z=382.1[M+H]+。
(4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲醇
在冰水浴条件下,向化合物3A(87mg,0.23mmol)的二氯甲烷(4mL)的溶液中缓慢加入三溴化硼(0.46mL,0.46mmol)的二氯甲烷溶液,反应液在零度搅拌一小时;反应液通过二氯甲烷稀释,饱和的碳酸氢钠水溶液洗涤两次,有机相浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=4/1)到得标题化合物(45mg,52%),为白色固体。
MS(ESI):m/z=368.0[M+H]+。
2-(溴甲基)-N-(2-氯-[1,1’-联苯基]-3-基)噻唑并[4,5-c]吡啶-4-胺
在冰水浴条件下,向化合物3B(45mg,0.12mmol)的二氯甲烷(4mL)的溶液,缓慢加入三溴化磷(65mg,0.24mmol),反应液在零度搅拌一小时;反应液通过二氯甲烷稀释,饱和的碳酸氢钠水溶液洗涤两次,有机相浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=8/1)到得标题化合物(35mg,68%),为白色固体。
MS(ESI):m/z=430.0[M+H]+。
2-(((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)氨基)乙酰胺
向化合物3C(10mg,0.023mmol),2-氨基乙酰胺盐酸(8mg,0.069mmol)的乙腈溶液(3mL)中加入无水碳酸钾(19mg,0.138mmol),反应液继续搅拌过夜,过滤,浓缩,残渣通过制备型高效液相色谱纯化获得目标产物(4mg,41%),为白色固体。
MS(ESI):m/z=424.1[M+H]+.
1H NMR(400MHz,CD3OD)δ8.71(dd,J=8.3,1.5Hz,1H),8.04(d,J=5.7Hz,1H),7.45-7.39(m,5H),7.39-7.34(m,2H),7.01(dd,J=7.6,1.5Hz,1H),4.25(s,2H),3.40(s,2H)。
实施例4
(2S,4S)-1-((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)-4-羟基吡咯烷-2-羧酸
4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-甲醛
在冰水浴的条件下,向化合物3B(100mg,0.27mmol)的二氯甲烷溶液(5mL)中分批加入戴斯-马丁氧化剂(229mg,0.54mmol),反应液继续搅拌一小时,反应用水淬灭,萃取,干燥,浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=10/1)到得标题化合物(70mg,71%),为黄色固体。
MS(ESI):m/z=366.1[M+H]+。
甲基(2S,4S)-1-((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)-4-羟基吡咯烷-2-羧酸酯
向化合物4A(40mg,0.11mmol),甲基(2S,4S)-4-羟基吡咯烷-2-羧酸酯盐酸(40mg,0.22mmol)的二氯甲烷(5mL)溶液中加入催化量的醋酸(1滴),反应液常温搅拌三个小时,加入氰基硼氢化钠(14mg,0.22mmol),继续搅拌过夜,反应完全后加水淬灭,萃取,过滤,浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=2/1)到得标题化合物(15mg,28%),为白色固体。
MS(ESI):m/z=495.1[M+H]+。
(2S,4S)-1-((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)-4-羟基吡咯烷-2-羧酸
向化合物4B(15mg,0.030mmol)的甲醇(3mL)和水(0.5mL)溶液中加入氢氧化锂一水合物(3mg,0.060mmol),反应液继续常温搅拌一小时,浓缩,残渣通过制备型高效液相色谱纯化获得目标产物(7mg,50%),为白色固体。
MS(ESI):m/z=481.1[M+H]+。
1H NMR(400MHz,CD3OD)δ8.68(dd,J=8.2,1.5Hz,1H),8.02(d,J=5.7Hz,1H),7.45-7.31(m,7H),7.00(dd,J=7.5,1.6Hz,1H),4.58(s,1H),4.48(d,J=15.6Hz,1H),4.29(s,1H),4.18(d,J=15.3Hz,1H),3.54-3.45(m,1H),3.21-3.19(m,1H),2.91-2.84(m,1H),2.55-2.46(m,1H),1.99-1.90(m,1H)。
实施例5
2-(((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)氨基)乙烷-1-醇
目标化合物在类似于实施例4的条件下制备自化合物4A和2-氨基乙烷-1-醇。
MS(ESI):m/z=411.1[M+H]+。
1H NMR(400MHz,MeOD-d4)δ8.72(dd,J=8.3,1.5Hz,1H),8.04(d,J=5.7Hz,1H),7.48-7.32(m,7H),7.01(dd,J=7.6,1.5Hz,1H),4.27(s,2H),3.69(t,J=5.5Hz,2H),2.86(t,J=5.5Hz,2H)。
实施例6
(R)-1-((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)吡咯烷-3-醇
目标化合物在类似于实施例3的条件下制备自化合物3C和(R)-吡咯烷-3-醇。
MS(ESI):m/z=437.1[M+H]+。
1H NMR(400MHz,CD3OD)δ8.72(dd,J=8.3,1.6Hz,1H),8.03(d,J=5.7Hz,1H),7.44-7.32(m,7H),7.00(dd,J=7.6,1.6Hz,1H),4.58(s,1H),4.40-4.34(m,1H),4.13(d,J=3.2Hz,2H),3.01-2.89(m,2H),2.75-2.67(m,2H),2.20-2.10(m,1H),1.80-1.72(m,1H)。
实施例7
(S)-1-((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)吡咯烷-3-醇
目标化合物在类似于实施例3的条件下制备自化合物3C和(S)-吡咯烷-3-醇。
MS(ESI):m/z=437.1[M+H]+。
1H NMR(400MHz,CD3OD)δ8.72(dd,J=8.3,1.6Hz,1H),8.04(d,J=5.7Hz,1H),7.44-7.33(m,7H),7.01(dd,J=7.6,1.6Hz,1H),4.58(s,1H),4.41-4.35(m,1H),4.14(d,J=3.2Hz,2H),3.00-2.89(m,2H),2.76-2.67(m,2H),2.22-2.12(m,1H),1.81-1.72(m,1H)。
实施例8
((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸
目标化合物在类似于实施例3的条件下制备自化合物3C和甘氨酸。
MS(ESI):m/z=425.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.77(d,J=8.8Hz,1H),8.67(s,1H),8.06(d,J=5.4Hz,1H),7.53(d,J=5.4Hz,1H),7.48-7.38(m,6H),7.02(dd,J=7.7,1.5Hz,1H),4.17(s,2H),3.09(s,2H)。
实施例9
2-(((4-((2-氯-3’-(3-氯丙氧基)-2’-甲基-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)氨基)乙烷-1-醇
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=517.1[M+H]+。
1H NMR(400MHz,CD3OD)δ8.75(d,J=6.9Hz,1H),8.05(d,J=5.7Hz,1H),7.41(d,J=5.7Hz,1H),7.38-7.31(m,1H),7.19(t,J=7.9Hz,1H),6.95(d,J=7.7Hz,1H),6.88(dd,J=7.5,1.5Hz,1H),6.74(d,J=7.6Hz,1H),4.25(s,2H),4.17(m,2H),3.79(t,J=6.4Hz,2H),3.68(t,J=5.5Hz,2H),2.84(t,J=5.5Hz,2H),2.30-2.22(m,2H),1.96(s,3H)。
实施例10
2-(((4-((2-氯-3-(2,3-二氢苯并[b][1,4]二噁英-6-基)苯基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)氨基)乙烷-1-醇
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=469.1[M+H]+。
1H NMR(400MHz,CD3OD)δ8.65(dd,J=8.3,1.5Hz,1H),8.04(d,J=5.7Hz,1H),7.40(d,J=5.7Hz,1H),7.35-7.29(m,1H),6.99(dd,J=7.6,1.6Hz,1H),6.90-6.85(m,3H),4.35(s,2H),4.27(s,4H),3.75-3.69(m,2H),2.97-2.91(m,2H)。
实施例11
2-(((4-((2-氯-3’-(2-吗啉代乙氧基)-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)氨基)乙烷-1-醇
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=540.1[M+H]+。
1H NMR(400MHz,CD3OD)δ8.70(dd,J=8.3,1.5Hz,1H),8.01(d,J=5.7Hz,1H),7.36(d,J=5.7Hz,1H),7.32(m,2H),7.00-6.93(m,4H),4.23(s,2H),4.15(t,J=5.5Hz,2H),3.72-3.65(m,6H),2.84(t,J=5.5Hz,2H),2.79(t,J=5.5Hz,2H),2.61-2.54(m,4H)。
实施例12
1-(4-((2’-氯-3’-((2-(((2-羟基乙基)氨基)甲基)噻唑并[4,5-c]吡啶-4-基)氨基)-[1,1’-联苯基]-3-基)氧代)丁基)吡咯烷-3-醇
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=568.6[M+H]+。
1H NMR(400MHz,CD3OD)δ8.70(dd,J=8.3,1.6Hz,1H),8.03(d,J=5.7Hz,1H),7.40(d,J=5.7Hz,1H),7.38-7.29(m,2H),7.03-6.90(m,4H),4.34(ddd,J=9.5,6.3,3.2Hz,1H),4.25(s,2H),4.03(t,J=6.1Hz,2H),3.68(t,J=5.4Hz,2H),2.93-2.73(m,4H),2.70-2.50(m,4H),2.17-2.06(m,1H),1.86-1.68(m,5H)。
实施例13
((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸甲酯
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=438.9[M+H]+。
1H NMR(400MHz,CD3OD)δ8.72(dd,J=8.3,1.6Hz,1H),8.04(d,J=5.7Hz,1H),7.46-7.33(m,7H),7.01(dd,J=7.6,1.6Hz,1H),4.27(s,2H),3.71(s,3H),3.56(s,2H)。
实施例14
((4-((2-氯-3’-(3-((3-羟基丙基)(甲基)氨基)丙氧基)-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=570.5[M+H]+。
1H NMR(400MHz,CD3OD)δ8.70(d,J=7.0Hz,1H),8.04(d,J=5.7Hz,1H),7.40(d,J=5.6Hz,1H),7.34(m,2H),7.04-6.94(m,4H),4.38(s,2H),4.15(t,J=5.7Hz,2H),3.67(t,J=5.7Hz,2H),3.44(s,2H),3.29-3.23(m,2H),3.18(t,J=7.4Hz,2H),2.82(s,3H),2.27-2.15(m,2H),1.95-1.85(m,2H)。
实施例15
((4-((2-氯-3’-(3-(3-羟基吡咯烷-1-基)丙氧基)-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=568.5[M+H]+。
1H NMR(400MHz,CD3OD-d4)δ8.71(d,J=7.0Hz,1H),8.06(d,J=5.7Hz,1H),7.41(d,J=5.7Hz,1H),7.35(td,J=8.1,1.5Hz,2H),7.04–6.94(m,4H),4.53(s,1H),4.43(s,2H),4.15(t,J=5.7Hz,2H),3.64–3.53(m,2H),3.49(s,2H),3.42–3.32(m,4H),2.26–2.18(m,3H),2.07-1.95(m,1H)。
实施例16
((4-((2-氯-3’-(3-(3-羟基吡咯烷-1-基)丙氧基)-2’-甲基-[1,1’-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸
目标化合物根据实施例3方法,替换相应原料获得。
MS(ESI):m/z=582.5[M+H]+。
1H NMR(400MHz,CD3OD)δ8.74(dd,J=8.3,1.5Hz,1H),8.07(d,J=5.7Hz,1H),7.42(d,J=5.7Hz,1H),7.35(m,1H),7.19(m,1H),6.95(d,J=8.3Hz,1H),6.87(dd,J=7.5,1.5Hz,1H),6.76(d,J=7.0Hz,1H),4.54-4.47(m,1H),4.37(s,2H),4.18-4.11(m,2H),3.57-3.44(m,2H),3.42(s,2H),3.40-3.27(m,4H),2.27-2.17(m,3H),2.14-1.94(m,4H)。
实施例17
2-(((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[5,4-c]吡啶-2-基)甲基)氨基)乙烷-1-醇
N-(2-氯-[1,1’-联苯基]-3-基)-2-甲硫基唑并[5,4-c]吡啶-4-胺
向4-氯-2-甲硫基唑并[5,4-c]吡啶(75mg,0.41mmol),2-氯-[1,1’-联苯基]-3-胺(116mg,0.57mmol)的甲苯(4mL)溶液中加入三(二苯亚甲基丙酮)二钯(36mg,0.04mmol),4,5-双二苯基膦-9,9-二甲基氧杂蒽(46mg,0.08mmol)和碳酸铯(267mg,0.82mmol),在氮气的保护下,反应液加热到90℃并搅拌8小时,反应液冷却后用硅藻土过滤,二氯甲烷洗脱,滤液浓缩,残渣通过正相快速分离纯化(石油醚/乙酸乙酯=9/1)得到目标化合物17B(120mg,83%),为浅黄色固体。
MS(ESI):m/z=351.9[M+H]+。
4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[5,4-c]吡啶-2-甲醛
室温下向化合物17B(40mg,0.11mmol)的1-甲基-2-吡咯烷酮(4mL)的溶液中加入二氧化锡(61mg,0.55mmol),混合物在微波下加热到120℃搅拌两小时,冷却后反应粗品经制备型高效液相色谱纯化得到标题化合物17C(20mg粗品,35%),为黄色固体。
MS(ESI):m/z=383.9[M+18+H]+。
2-(((4-((2-氯-[1,1’-联苯基]-3-基)氨基)噻唑并[5,4-c]吡啶-2-基)甲基)氨基)乙烷-1-醇
向实施例17C(20mg,0.035mmol),2-氨基乙烷-1-醇(8mg,0.14mmol)的二氯甲烷溶液中加入催化量的醋酸(1滴),反应液室温搅拌16小时后加入三乙酰氧基硼氢化钠(63mg,0.30mmol),反应液继续室温搅拌4小时,反应液用水(10mL)淬灭,二氯甲烷萃取三次(15mL*3),有机相合并干燥后浓缩,残渣通过制备型高效液相色谱纯化获得目标化合物(4mg,25%),为黄色固体。
MS(ESI):m/z=410.9[M+H]+。
1H NMR(400MHz,MeOD-d4)δ8.08(d,J=5.8Hz,1H),7.65(dd,J=8.1,1.6Hz,1H),7.45-7.33(m,7H),7.21(dd,J=7.7,1.6Hz,1H),4.33(s,2H),3.71(t,J=5.4Hz,2H),2.92(t,J=5.4Hz,2H)。
实施例18:
(S)-((4-((2,2'-二氯-3'-(6-甲氧基-5-((((5-羰基吡咯烷-2-基)甲基)氨基)甲基)吡啶-2-基)-[1,1'-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸
甲基((4-((3-溴-2-氯苯基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸酸酯
向化合物18A(100mg,0.23mmol),甘氨酸甲酯盐酸盐(58mg,0.46mmol)的乙腈溶液(3mL)中加入无水碳酸钾(191mg,1.38mmol),反应液常温搅拌过夜,待反应完成后,萃取,浓缩,粗品通过正相快速分离纯化(乙酸乙酯:石油醚=7:1)获得目标产物18B(80mg,79%),为淡黄色固体。
MS(ESI):m/z=440.7[M+H]+.
甲基((4-((2,2'-二氯-3'-(5-甲酰基-6-甲氧基吡啶-2-基)-[1,1'-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸酸酯
向化合物18B(80mg,0.18mmol),6-(2-氯-3-(4,4,5,5-四甲基-1,3,2-二噁硼戊环-2-基)苯基)-2-甲氧基尼古丁醛(101mg,0.27mmol),碳酸钾(75mg,0.54mmol)的二氧六环(3mL)和水(0.5mL)的混合物中,加入1,1'-双二苯基膦基二茂铁二氯化钯二氯甲烷络合物(15mg,0.018mmol),反应液在氮气保护下,加热到95℃搅拌两个小时。过滤,浓缩,残渣通过正相快速分离纯化(乙酸乙酯:石油醚=8:1)获得目标产物18C(100mg,89%),为淡黄色固体。MS(ESI):m/z=607.9[M+H]+.
甲基(S)-((4-((2,2'-二氯-3'-(6-甲氧基-5-((((5-羰基吡咯烷-2-基)甲基)氨基)甲基)吡啶-2-基)-[1,1'-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸酸酯
向化合物18C(100mg,0.16mmol),(S)-5-(氨基甲基)吡咯烷-2-酮盐酸(121mg,0.80mmol)的N,N-二甲基甲酰胺混合溶液中,加入N,N-二异丙基乙胺(104mg,0.80mmol),反应液加热到50℃并在该温度下搅拌两个小时后。分批加入三乙酰氧基硼氢化钠(170mg,0.80mmol),反应液继续搅拌一小时。待反应完成后,用少量的甲醇淬灭,反应液通过反相快速分离纯化(80%乙腈-10nmol/mL浓度碳酸氢铵水溶液)获得目标产物18D(70mg,63%),为淡黄色固体。
MS(ESI):m/z=706.0[M+H]+.
(S)-((4-((2,2'-二氯-3'-(6-甲氧基-5-((((5-羰基吡咯烷-2-基)甲基)氨基)甲基)吡啶-2-基)-[1,1'-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸
向化合物18D(70mg,0.10mmol)的甲醇(3mL)和水(0.5mL)的混合物中,加入氢氧化锂一水合物(17mg,0.40mmol),反应液常温下搅拌两个小时。待反应完成后,反应液通过反相快速分离纯化(35%的乙腈-0.1%的甲酸水溶液洗脱)获得目标产物实施例18(30mg,43%),为淡黄色固体。
MS(ESI):m/z=692.0[M+H]+.
NMR:1H NMR(400MHz,DMSO-d6)δ8.84(d,J=8.7Hz,1H),8.63(s,1H),8.08(d,J=5.6Hz,1H),7.79(d,J=7.4Hz,1H),7.68(s,1H),7.64(dd,J=7.8,1.4Hz,1H),7.55(d,J=5.6Hz,1H),7.51(m,1H),7.44(m,1H),7.39(dd,J=7.7,1.7Hz,1H),7.25(d,J=7.7Hz,1H),7.02(d,J=7.8Hz,1H),4.18(s,2H),3.89(s,3H),3.68(s,2H),3.60(m,1H),3.22(s,2H),2.52(d,J=5.8Hz,2H),2.10-2.00(m,3H),1.72-1.60(m,1H).
实施例19:
(5-甲基-2-羰基-1,3-二噁唑-4-基)甲基(S)-((4-((2,2'-二氯-3'-(6-甲氧基-5-((((5-羰基吡咯烷-2-基)甲基)氨基)甲基)吡啶-2-基)-[1,1'-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸酸酯
(5-甲基-2-羰基-1,3-二噁唑-4-基)甲基(S)-((4-((2,2'-二氯-3'-(6-甲氧基-5-((((5-羰基吡咯烷-2-基)甲基)氨基)甲基)吡啶-2-基)-[1,1'-联苯基]-3-基)氨基)噻唑并[4,5-c]吡啶-2-基)甲基)甘氨酸酸酯
向实施例18(80mg,0.12mmol),无水碳酸钾(50mg,0.36mmol)的N,N-二甲基甲酰胺(3mL)的溶液中,加入4-(氯甲基)-5-甲基-1,3-二噁唑-2-酮(36mg,0.24mmol),反应液常温下搅拌过夜。待反应完成后,反应液通过反相快速分离纯化(65%的乙腈-0.1%的甲酸水溶液洗脱)获得目标产物实施例19(18mg,18%),为白色固体。
MS(ESI):m/z=804.2[M+H]+.
1H NMR(400MHz,DMSO-d6)δ8.84(dd,J=8.3,1.4Hz,1H),8.62(s,1H),8.09(d,J=5.6Hz,1H),7.79(d,J=7.6Hz,1H),7.67(s,1H),7.64(dd,J=7.7,1.7Hz,1H),7.56(d,J=5.6Hz,1H),7.51(m,1H),7.45(m,1H),7.39(dd,J=7.5,1.7Hz,1H),7.25(d,J=7.6Hz,1H),7.02(dd,J=7.5,1.4Hz,1H),4.97(s,2H),4.21(d,J=5.6Hz,2H),3.89(s,3H),3.68(s,2H),3.65-3.58(m,1H),3.55(d,J=6.6Hz,2H),3.51-3.41(m,1H),2.52(d,J=5.9Hz,2H),2.11(s,3H),2.10-2.01(m,3H),1.72-1.60(m,1H).
以下各个化合物采用与实施例18-19类似的方法,替换相应原料获得。
测试例1:检测化合物对PD-1/PD-L1蛋白相互结合的抑制效应
采用PD-1/PD-L1均相时间分辨荧光(Homogenous Time-Resolved Fluorescence,HTRF)检测技术来检测化合物跟PD-L1的结合能力。
选用PD1/PD-L1binding assay试剂盒(Cisbio,Cat#63ADK000CPDEC),该试剂盒包含Tag 1-PD-L1和Tag 2-PD-1两个蛋白,及Anti-Tag1-Eu3+和Anti-Tag2-XL 665两个抗体。检测原理:Anti-tag1-Eu3+作为HTRF的供体,Anti-Tag2-XL 665作为HTRF的受体,当Tag 1-PD-L1和Tag 2-PD-1相互作用时,加入的HTRF供体和受体相互靠近,供体接受到激发能量后,将部分能量转移到受体,会产生665nm发射光。当加入化合物阻断了PD1/PD-L1相互作用时,只产生620nm发射光。通过比较665nm/620nm的比值,来确定化合物的抑制效果。Tag 1-PD-L1用Diluent buffer(cat#62DLBDDF)稀释成工作浓度10nM,Tag 2-PD-1用Diluentbuffer稀释成工作浓度500nM,Anti-Tag1-Eu3+用detection buffer(cat#62DB1FDG)按1:100稀释,Anti-Tag2-XL 665用detection buffer按1:20稀释,待检测化合物用diluentbuffer梯度稀释成2X的终浓度。在384孔板中每孔先加入2μL化合物,再分别先后加入4μLTag 1-PD-L1,4μL Tag 2-PD-1,室温孵育15分钟。加入5μL Anti-Tag1-Eu3+和5μL Anti-Tag2-XL 665,室温孵育过夜,用BioTekSynergyTMNeo2多功能酶标仪检测,获得665nm/620nm比值。用PrismGraphd 5.02拟合IC50曲线。
表1本发明部分化合物的IC50值
字母A代表IC50小于100nM;
字母B代表IC50为100nM至1uM;
字母C代表IC50为大于1uM;
结果显示,本发明中化合物可在不同浓度下有效抑制PD-1/PD-L1的结合。因此可用于与PD-1/PD-L1互相结合相关的疾病治疗中。
测试例2:细胞学NFAT报告基因实验
PD1/PD-L1的细胞学实验需要有两种细胞,PD-1效应细胞和PD-L1 aAPC/CHO-K1细胞,其中PD-1效应细胞表达人PD-1蛋白和由NFAT驱动的荧光素酶报告基因,PD-L1 aAPC/CHO-K1细胞表达PD-L1蛋白和anti-CD3 antibody。当这两种细胞共培养时,PD-1/PD-L1的相互作用会抑制TCR至NFAT-RE的信号传递,中断NFAT-RE介导的荧光信号。当加入PD-1或PD-L1的抑制剂时,阻断了PD-1/PD-L1的相互作用,解除了对TCR至NFAT-RE通路的信号抑制,使荧光信号增强,通过荧光信号的强弱来判断抑制剂的阻断效果。
实验第一天,将复苏的PD-L1 aAPC/CHO-K1细胞消化处理,离心后用培养基(90%Ham’s F-12/10%FBS)将浓度调为2.5*105/mL,按每孔40ul,1*104细胞的量铺在384孔板中,置于培养箱中过夜培养。第二天,先将待测化合物用检测buffer(99%RPMI1640/1%FBS)按梯度稀释到所需检测浓度的2倍,PD-1细胞离心后用检测buffer调成浓度为6.25*105/mL。将过夜培养的384孔板中的培养基吸干,每孔加入20ul稀释好的化合物,再加入20ul PD-1细胞,在细胞培养箱中孵育6小时后,每孔再加入20ul Bio-Glo试剂(Promega,cat#G7940),10分钟后,用多功能酶标仪读板。每块板需设置阴性对照(只加细胞,不加化合物),和空白对照(只加检测buffer)。根据荧光值,用prism5来分析化合物的抑制活性。
结果显示,本发明化合物能够有效阻断PD-1/PD-L1的相互作用,半活抑制浓度与临床阶段的PD1抑制剂相当或更佳。
测试例3:Human PBMC功能学实验
Human PBMC功能学实验需要两种细胞,human PBMC细胞和PD-L1aAPC/CHO-K1细胞(CHO-K1细胞表达全长的human PD-L1蛋白及anti-hCD3抗体)。当这两种细胞共培养时,aAPC细胞表达的anti-hCD3抗体与PBMC表面CD3结合,刺激PBMC活化增殖,但PD-1/PD-L1的相互作用会抑制TCR信号传递,当加入PD1或PD-L1抑制剂时,阻断了PD-1/PD-L1的相互作用,解除了对TCR通路的信号。通过检测PBMC活化后细胞表面标志CD25,PD1以及胞内细胞因子IFNr变化判断抑制剂的阻断效果。
实验第一天,将复苏的PD-L1 aAPC/CHO-K1细胞和PD-L1Negative细胞消化处理,离心后用培养基(90%F12+10%FBS)将细胞浓度调整为2*105/mL,按每孔100ul,2*104细胞的量铺在96孔板中,置于培养箱中过夜培养。第二天,用含10ug/mlmitomycin的培养基处理细胞,37℃放置4h,然后用PBS洗板三次。同时配制待测化合物,按梯度稀释到所需检测浓度的2倍。PBMC细胞按操作要求复苏并调整浓度到1*106/mL,板中先加入50ul化合物,然后加入50ul PBMC细胞,细胞培养箱中孵育三天后分别收集细胞上清用于ELISA检测细胞因子IFNr的变化,收集细胞流式检测CD25,PD1的变化。
结果显示,本发明化合物能够有效阻断PD-1/PD-L1的相互作用,半活抑制浓度与临床阶段的PD1抑制剂相当或更佳。
测试例4:本发明中小分子抑制剂治疗肿瘤体内药效实验
建立皮下移植肿瘤的小鼠模型,以检查这些化合物对肿瘤生长的体内抑制效果。方法如下:将培养的特定肿瘤细胞消化后离心收集细胞,用无菌生理盐水清洗两遍后计数,用生理盐水调整细胞浓度至所需的浓度,取0.2ml细胞混悬液接种到C57BL/6或者Balb/c免疫健全小鼠皮下。接种后观察肿瘤生长至特定大小,动物随机分组,每组6-7只,称重后给药,待测化合物每天给药一次,分组包括:载体组,对照抗PD-L1抗体组,待测化合物组。小鼠每周检测肿瘤生长,共大约6周,待肿瘤体积达到肿瘤终点后,称量小鼠体重,并进行安乐死。剥取肿瘤组织,脾脏组织及血液样本。计算肿瘤抑制率,检测肿瘤、脾脏及血液样本中免疫细胞组成,计算待测化合物免疫调节活性。
结果显示,本发明化合物能够在荷瘤小鼠中有效抑制肿瘤生长,其抑制效果与临床阶段的PD1抑制剂相当或更佳。
测试例5:本发明中小分子抑制剂联合化疗药治疗肿瘤体内药效实验
建立皮下移植肿瘤的小鼠模型,以检查这些化合物对肿瘤生长的体内抑制效果。方法如下:将培养的特定肿瘤细胞消化后离心收集细胞,用无菌生理盐水清洗两遍后计数,用生理盐水调整细胞浓度至所需的浓度,取0.2ml细胞混悬液接种到C57BL/6或者Balb/c免疫健全小鼠皮下。接种后观察肿瘤生长至特定大小,动物随机分组,每组6-7只,称重后给药,待测化合物与联用药贝伐/卡铂/紫杉醇/培美曲塞按照联合给药方案给药,分组包括:载体组,测试化合物联合化疗药组,化疗药组,测试化合物组。小鼠每周检测肿瘤生长,共大约6周,待肿瘤体积达到肿瘤终点后,称量小鼠体重,并进行安乐死。剥取肿瘤组织,脾脏组织及血液样本。计算肿瘤抑制率,检测肿瘤、脾脏及血液样本中免疫细胞组成,计算待测化合物及联合用药的免疫调节活性。
结果显示,本发明化合物联合化疗药物能够在荷瘤小鼠中更有效抑制肿瘤生长,其抑制效果优于单用化疗药。
测试例6:本发明中小分子抑制剂联合免疫调节剂治疗肿瘤体内药效实验
建立皮下移植肿瘤的小鼠模型,以检查这些化合物对肿瘤生长的体内抑制效果。方法如下:将培养的特定肿瘤细胞消化后离心收集细胞,用无菌生理盐水清洗两遍后计数,用生理盐水调整细胞浓度至所需的浓度,取0.2ml细胞混悬液接种到C57BL/6或者Balb/c免疫健全小鼠皮下。接种后观察肿瘤生长至特定大小,动物随机分组,每组6-7只,称重后给药,待测化合物与联用药Nivolumab/Ipilimumab按照联合给药方案给药,分组包括:载体组,测试化合物联合免疫调节药组,免疫调节药组,测试化合物组。小鼠每周检测肿瘤生长,共大约6周,待肿瘤体积达到肿瘤终点后,称量小鼠体重,并进行安乐死。剥取肿瘤组织,脾脏组织及血液样本。计算肿瘤抑制率,检测肿瘤、脾脏及血液样本中免疫细胞组成,计算待测化合物及联合用药的免疫调节活性。
结果显示,本发明化合物联合免疫调节剂药物能够在荷瘤小鼠中更有效抑制肿瘤生长,其抑制效果优于单用免疫调节剂。
测试例7:本发明中小分子抑制剂小鼠药代动力学实验
分别单次静脉(IV)和口服(PO)给予ICR小鼠测试化合物,于不同时间点采集血样,LC-MS/MS测定小鼠血浆中受试物的浓度并计算相关参数。具体如下:取所需量供试品,溶于5%DMSO+10%Solutol+85%注射用水中,配成所需浓度的溶液,用于静脉或口服。给药实验开始时动物年龄约6-8周。静脉采血时间:给药后0.083h,0.25h,0.5h,1h,2h,4h,8h和24h。口服采血时间:给药后0.25h,0.5h,1h,2h,4h,6h,8h和24h。建立生物样品分析方法及样品检测方法。过不同时间点的血药浓度数据,运用Phoenix WinNonlin 7.0软件计算药代动力学参数,如AUC(0-t),AUC(0-∞),T1/2,Cmax,Tmax和MRT等。
结果显示,本发明化合物具有优异的药代动力学性质。
测试例8:本发明中小分子抑制剂大鼠药代动力学实验
分别单次静脉(IV)和口服(PO)给予SD大鼠测试化合物,于不同时间点采集血样,LC-MS/MS测定大鼠血浆中受试物的浓度并计算相关参数。具体如下:取所需量供试品,溶于5%DMSO+10%Solutol+85%注射用水中,配成所需浓度的溶液,用于静脉或口服。给药实验开始时动物年龄约6-8周。静脉采血时间:给药后0.083h,0.25h,0.5h,1h,2h,4h,8h和24h。口服采血时间:给药后0.25h,0.5h,1h,2h,4h,6h,8h和24h。建立生物样品分析方法及样品检测方法。过不同时间点的血药浓度数据,运用Phoenix WinNonlin 7.0软件计算药代动力学参数,如AUC(0-t),AUC(0-∞),T1/2,Cmax,Tmax和MRT等。
结果显示,本发明化合物具有优异的药代动力学性质。
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (10)
1.一种如下式I所示的化合物,其立体异构体或其互变异构体,或其药学上可接受的盐、水合物或溶剂化物:
其中,
M选自O或NH;
X2选自下组:N、NR3、CR3、O、S、N=CR3、CR3=N或CR3=CR3;
X4选自下组:N、NR3、CH、O、S、N=CH、CH=N或CH=CH;
且X2和X4中有且仅有一个为选自下组的基团:CR3=CR3、N=CR3、或CR3=N(在X4中R3为H);
X1和X5各自独立地选自下组:N、CH、O或S;
X3选自下组:N、CR3、O或S;
且X3或X4中至少一个为O、S或N;
Y1和Y2各自独立地为N或C;
Z1、Z2和Z3各自独立地为N或CR4;
R1选自下组:H、卤素、CN、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基;
R2选自下组:取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂芳基、或取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂环基;且所述的R2基团上有一个或多个氢原子被R5取代;
Ra和Rb各自独立地选自下组:H、-(C=O)-取代或未取代的C1-C8烷基、取代或未取代的C1-C8烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C8烷胺基、取代或未取代的C1-C8烷氧基、取代或未取代的C3-C10环烷基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的3-10元杂环烷基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基、或取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂环基;
或所述的Ra和Rb与相邻的N原子共同构成取代或未取代的具有1-3个选自下组N、S和O的杂原子的5-10元杂环基;
所述的R4选自下组:H、卤素、CN、取代或未取代的C1-C6烷基、取代或未取代的C1-C6烷氧基;
所述的R5选自下组:H、CN、卤素、取代或未取代的(-L1-L2-(C1-C8亚烷基)-(取代或未取代的5-7元杂芳基))、取代或未取代的(-L1-L2-(C1-C8亚烷基)-N(Ra)(Rb))、-O-取代或未取代的(-(C1-C8亚烷基)-O-(C1-C8亚烷基)-N(Ra)(Rb))、或取代或未取代的选自下组的基团:C6-C10芳基、具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基、-L1-L2-5-10元杂芳基-(C1-C8亚烷基)-N(Ra)(Rb);其中,所述的L1和L2各自独立地选自下组:无、取代或未取代的C1-C8亚烷基、-NH-C(=O)-NH-、-C(=O)-NH-、-O-、-S-或-NH-;或两个R5与相连的碳原子共同构成选自下组的基团:取代或未取代的5-7元杂芳基、取代或未取代的5-7元杂环基;
除非特别说明,所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代:卤素、C1-C6烷氧基、卤代的C1-C6烷氧基、C3-C8环烷基、卤代的C3-C8环烷基、甲基砜基、-S(=O)2NH2、氧代(=O)、-CN、羟基、-NH2、C1-C6胺基、羧基、C1-C6酰胺基(-C(=O)-N(Rc)2或-NH-C(=O)(Rc),Rc为H或C1-C5的烷基)、或取代或未取代的选自下组的基团:C1-C6烷基、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的5-10元杂环基(包括并环、螺环)、-(CH2)-C6-C10芳基、-(CH2)-(具有1-3个选自N、S和O的杂原子的5-10元杂芳基),且所述的取代基选自下组:卤素、C1-C6烷基、C1-C6烷氧基、氧代、-CN、-OH、C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基;
附加条件是式I化合物为化学上稳定的结构。
7.一种药物组合物,其特征在于,包含(1)如权利要求1所述的化合物或其立体异构体或互变异构体,或其药学上可接受的盐、水合物或溶剂化物;(2)药学上可接受的载体。
8.如权利要求1所述的化合物或其立体异构体或互变异构体,或其药学上可接受的盐、水合物或溶剂化物或如权利要求7所述的药物组合物的用途,其特征在于,用于制备预防和/或治疗与PD-1/PD-L1的活性或表达量相关的疾病的药物组合物。
9.如权利要求8所述的用途,其特征在于,所述的疾病选自下组:肿瘤、病原体感染、自身免疫应答相关疾病。
10.一种PD-1/PD-L1抑制剂,其特征在于,所述抑制剂包含权利要求1所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物或溶剂化物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910503368.2A CN112062780A (zh) | 2019-06-11 | 2019-06-11 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
PCT/CN2019/098925 WO2020025030A1 (zh) | 2018-08-01 | 2019-08-01 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
CN201980051399.7A CN112638899B (zh) | 2018-08-01 | 2019-08-01 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
EP19843979.6A EP3831823A4 (en) | 2018-08-01 | 2019-08-01 | PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION |
US17/264,657 US20210347785A1 (en) | 2018-08-01 | 2019-08-01 | Preparation and application of aromatic compound having immunoregulatory function |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910503368.2A CN112062780A (zh) | 2019-06-11 | 2019-06-11 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112062780A true CN112062780A (zh) | 2020-12-11 |
Family
ID=73658464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910503368.2A Pending CN112062780A (zh) | 2018-08-01 | 2019-06-11 | 一类具有免疫调节功能的芳香化合物的制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112062780A (zh) |
-
2019
- 2019-06-11 CN CN201910503368.2A patent/CN112062780A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112638899A (zh) | 一类具有免疫调节功能的芳香化合物的制备和应用 | |
CN110790770A (zh) | 一类具有免疫调节功能的芳香胺化合物的制备和应用 | |
KR20210124296A (ko) | 면역조절제, 조성물 및 이의 방법 | |
JP2022516401A (ja) | Irak分解剤およびそれらの使用 | |
CN113637005A (zh) | 用于癌症治疗的kras抑制剂 | |
CN110790758A (zh) | 一类具有免疫调节功能的含n杂环化合物的制备和应用 | |
CA2989684A1 (en) | Hpk1 inhibitors and methods of using same | |
KR20180083421A (ko) | 단백질 키나아제 억제제 및 이의 제조방법과 의학적 용도 | |
WO2014113191A1 (en) | Hedgehog pathway signaling inhibitors and therapeutic applications thereof | |
KR20220119455A (ko) | T 세포 활성화제로서 유용한 치환된 비시클릭 피페리딘 유도체 | |
US20230339891A1 (en) | Uracil derivatives as mer-axl inhibitors | |
CN110156656B (zh) | 五元杂芳环衍生物、其制备方法、药物组合物及应用 | |
KR20230143632A (ko) | Irak 분해제 및 이의 용도 | |
TW202136242A (zh) | Smarca降解劑及其用途 | |
CN113336747A (zh) | 新型hpk1抑制剂及其制备方法和应用 | |
CN114641474B (zh) | 一类具有免疫调节功能的含n杂环化合物的制备和应用 | |
WO2023104043A1 (zh) | 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用 | |
CN112062780A (zh) | 一类具有免疫调节功能的芳香化合物的制备和应用 | |
TW202227063A (zh) | 治療癌症之方法 | |
CN115433210A (zh) | 一类具有免疫调节功能的化合物的制备和应用 | |
CN117157284A (zh) | Ctla-4小分子降解剂及其应用 | |
JP2023512208A (ja) | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 | |
JP2024515545A (ja) | がん治療のためのピリジニル置換オキソイソインドリン化合物 | |
WO2023220425A1 (en) | Bcl-xl/bcl-2 degraders and uses thereof | |
CN116490069A (zh) | Stat降解剂和其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201211 |